Regional variation in non-traumatic major lower limb amputation in England: observational study of linked primary and secondary care data
- PMID: 40137559
- PMCID: PMC11938355
- DOI: 10.1093/bjsopen/zraf004
Regional variation in non-traumatic major lower limb amputation in England: observational study of linked primary and secondary care data
Abstract
Background: Peripheral artery disease and diabetes are the main primary risk factors for non-traumatic major lower limb amputation. Regional variation in incidence of major lower limb amputation has yet to be fully described in terms of these risk factors and explained. The aim of this study was to estimate yearly incidence of major lower limb amputation over a 10-year interval (2010-2019) across England, by related condition and by region and, additionally, to investigate reasons for regional variation.
Methods: This observational study utilized primary care (Clinical Practice Research Datalink Aurum), secondary care (Hospital Episode Statistics), death and demographic data in England. Adults registered with a practice using Clinical Practice Research Datalink Aurum and with Hospital Episode Statistics linkage were included. Patients with a record of major lower limb amputation during the interval 1 January 2010 to 31 December 2019 were identified and yearly incidence rates of major lower limb amputation were calculated. Co-morbidities analysed were cardiovascular disease (including coronary artery disease, peripheral artery disease and cerebrovascular disease), diabetes (of any type) and cancer. Demographic and socioeconomic covariates analysed were age, sex, ethnicity, deprivation level, region and urban/rural categorization.
Results: The study included 18 397 483 individuals, 8584 of which had a record of major lower limb amputation. The age-standardized yearly incidence rate of major lower limb amputation in England decreased by 30% from 11.2 per 100 000 person-years in 2010 to 7.8 in 2019. The incidence rate in those with diabetes fell by 30% over the 10-year interval, rose by 20% for those with both diabetes and cardiovascular disease, and changed little in those with cardiovascular disease. In 2019, the age-standardized incidence rate was highest in the North East (14.8 per 100 000 person-years) and lowest in the East of England (4.5 per 100 000 person-years). Between 2010 and 1019, incidence rates decreased across all regions, the largest decrease of 56% in the East Midlands and the smallest of 8% in the North East. Statistically significant regional variation remained after full adjustment for demographic, socioeconomic data and related conditions.
Conclusion: Whilst the incidence of major lower limb amputation is decreasing overall, significant regional variation in major lower limb amputation exists and is unexplained by demographic, socioeconomic and health data. Regional differences in service provision and accessibility should be investigated to provide further explanation.
© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd.
Figures




Similar articles
-
Turning Tides: Evolving Comorbidity Profiles, Demographic Shift, and the Unexpected Rise of Major Lower Extremity Amputations.Ann Surg. 2025 Sep 1;282(3):429-438. doi: 10.1097/SLA.0000000000006813. Epub 2025 Jun 23. Ann Surg. 2025. PMID: 40548585
-
Female patients have fewer limb amputations compared to male patients in the BEST-CLI trial.J Vasc Surg. 2025 Feb;81(2):366-373.e1. doi: 10.1016/j.jvs.2024.09.031. Epub 2024 Oct 4. J Vasc Surg. 2025. PMID: 39368637 Clinical Trial.
-
Risk factors contributing to 30-day and 1-year mortality event scores following major lower extremity amputation for limb ischemia.J Vasc Surg. 2025 Jul;82(1):216-228.e1. doi: 10.1016/j.jvs.2025.02.030. Epub 2025 Mar 5. J Vasc Surg. 2025. PMID: 40054791
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
References
-
- Centers for Diseases and Control Prevention . Preventing Diabetes-Related Amputations. 2023. https://www.cdc.gov/diabetes/diabetes-complications/preventing-diabetes-... (accessed 31 October 2024)
-
- Ahmad N, Thomas GN, Gill P, Torella F. The prevalence of major lower limb amputation in the diabetic and non-diabetic population of England 2003–2013. Diab Vasc Dis Res 2016;13:348–353 - PubMed
-
- Behrendt CA, Sigvant B, Szeberin Z, Beiles B, Eldrup N, Thomson IA et al. International variations in amputation practice: a VASCUNET report. Eur J Vasc Endovasc Surg 2018;56:391–399 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical